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Purpose or Objective: The purpose of this study was to 
investigate the effect of the modeling of the treatment table 
top on the agreement between calculations and 
measurements on the Delta4 phantom (Scandidos). Also, the 
effect of the most suitable way to determine the daily 
correction factor was investigated. 
 
Material and Methods: Two of our linear accelerators are 
equipped with the standard Elekta iBeam evo carbon fiber 
table top. In our treatment planning system, Pinnacle v9.0 
(Philips), the table top is modeled as a slab with dimensions 
equal to the width and height of the table top and with a 
density of 0.25 g/cm³. 
We extended the axial dimensions of the artificial CT-image 
set of the Delta4 phantom provided by Scandidos from 25 x 
25 cm² to 50 x 50 cm² by a home-made program written in 
java. This allows us to place the table top model below the 
phantom at the real distance, ie 7 cm. 15 IMRT plans for 
breast cancer were recalculated twice, once on the CT-
images of the Delta4 phantom provided by Scandidos and a 
second time on the extended CT-images with the table top 
model included. All plans consist of 5 to 6 beams (87 in total) 
from which 1 to 2 beams go through the table (23 in total). 
The plans were exported to the Delta4 software and 
measured. In case no table top model was included in the 
calculations, a daily correction factor based on the average 
of 4 beams (gantry angles of 0°, 90°, 180° and 270°) was 
applied. When the table top model was included, a daily 
correction factor based on 1 beam (gantry angle of 0°) was 
applied. A gamma criterion of 3%/3mm was used. Statistical 
analysis was done by paired t-tests. A p-value < 0.05 was 
considered as statistically significant. 
 
Results: Without the use of daily correction factors, the 
mean pass rate for the overall treatment plans was 
respectively 90.7% (±6.9 SD) and 95.2% (±3.0 SD) without and 
with the table top model applied. This difference is 
significant with p = 0.01. In the first group 4 out of 15 pass 
rates were > 95%, whereas in the second group this is 9 out of 
15. With the use of the proper daily correction factors, this 
increases to respectively 98.6% (±1.2 SD) and 99.1% (±0.9 SD). 
This difference is also significant with p = 0.04. In both 
groups, all pass rates were > 95%. 
For individual beams going through the table top, the mean 
pass rate was respectively 90.8% (±9.9 SD) and 99.0% (±1.9 
SD) without and with the table top model applied and 
without the use of daily correction factors (p = 0.0001). In 
the first group 10 out of 23 pass rates were > 95%, whereas in 
the second group this is 22 out of 23. With the use of the 
proper daily correction factors, this increases to respectively 
99.0% (±1.6 SD) and 99.9% (±0.4 SD) (p = 0.01). In the first 
group 22 out of 23 pass rates were > 95% and in the second 
group all pass rates were > 95%. 
 
Conclusion: The table top modeling results in a better 
agreement between measurements and calculations, both for 
total plans and individual beams. This agreement improves 
when proper correction factors are applied. 
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Purpose or Objective: In-vivo dose verification is the last 
step of a quality assurance procedure to ensure that the dose 
delivered during treatment is in agreement with the 
prescribed one.This work reports the in-vivo dosimetry (IVD) 
results obtained by the SOFTDISO software (Best Medical 
Italy) during VMAT prostate cancer treatments. 
 
Material and Methods: SOFTDISO is based on a method 
developed by a cooperation between INFN and UCSC. It 
reconstructs in quasi-real time (a few seconds at the end of 
the fraction therapy) (i) the dose at the isocenter (Diso) in 
the patient from the transit signal acquired by the EPID and 
(ii) the comparison between EPID images obtained during the 
fractions of the therapy. In particular for each beam and 
fraction, the R ratios between the dose reconstructed at the 
isocenter point, Diso, in single-arc (179-181°) VMAT plans for 
prostate targets and the dose calculated by the TPS, 
Diso,TPS (generally about 2 Gy for fraction) obtained by 
Oncentra Masterplan, were computed. The acceptance 
criteria was: 0.95≤R≤1.05. Moreover the γ-analysis (2%-2mm) 
between portal images supplied useful index about the beam 
delivery reproducibility with the Pγ<1>95% and γ mean<0.4. 
15 patients with prostate cancer were treated with 6 MV 
photon beam delivered by an Elekta Synergy Agility (Elekta, 
Crawley). Our protocol required, for each patient, the IVD in 
the first three treatment sessions after a CBCT based set-up 
correction and the IVD test once weekly afterwards for the 
rest of the treatment course when the CBCT scan was not 
acquired. 
 
Results: The IVD procedure supplied 105 tests and the 
average R was equal to 1.003 ± 0.028 (1SD), in a range 
between 0.949 and 1.058. The global R value for each single 
patient was well-within the 5% tolerance level. The γ-analysis 
between EPID images supplied Pγ<1≥97% in 80% of the tests. 
20% of the tests supplied 93% ≤P γ<1<95% due to small setup 
variations as verified by the CBCT required at the end of the 
fraction therapy. 
 
Conclusion: The IVD results supported the protocol about the 
CBCT carried out in the first three treatment sessions of the 
VMAT prostate cancer treatment. The facility of the real time 
test supplied by SOFTDISO allows a CBCT scan requirement 
after the daily-fraction that supplies IVD off tolerance level. 
The authors intend to apply this procedure to estimate 
protocols about the use of the CBCT scans for other 
pathologies as the head-neck tumors where heavy dose 
variations due to morphological changes can occurs during 
the therapy. 
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Purpose or Objective: The study was aimed to check 
radiotherapy treatment accuracy and definition of action 
levels during implementation of in vivo dosimetry for 
treatment pelvic cancer patients as a part of quality 
assurance program. 
 
Material and Methods: Calibration and corrections factors for 
in vivo entrance dose measurements for n-type Isorad 
semiconductor diodes for photon energy of 15 MV were 
determined as per recommendations published by European 
Society for Radiotherapy and Oncology (ESTRO) Booklet No.5. 
The pelvic cancer patients for in vivo measurements have 
been divided into groups, according to radiation techique 
used, in order to investigate and detect the groups for which 
the uncertainty was larger or for which a systematic error 
occurred. Initial tolerance/action levels for all groups were 
set at level of 5 %. 
 
Results: In this study, entrance dose measurements were 
performed for total 185 treatment fields, of 95 pelvic cancer 
patients over one year period. In 6 (6%) out of 95 patients, in 
vivo measurements exceeded the tolerances. The mean value 
and the standard deviation for different groups were: Rectum 
and gynecology (four field box): 0.6%±3.07%(1SD), Prostate 
(five fields with wedges): +1.0%±2.22%(1SD). All pelvic 
measurements: +0.77%±2.79%(1SD). Larger standard deviation 
was shown for four field box cases because two large errors 
were noticed. After the corrections, in vivo dosimetry was 
repeated in both cases and the results were within the 
